Shupeng Li

Dr. Shupeng Li

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in IET Systems Biology
Verified
Journal Article
Open access
ZXZijun Xu
Zijun Xu
BXBohan Xi
Bohan Xi
JHJiaming Huang
Jiaming Huang
LZLiqiang Zhang
Liqiang Zhang
SCSifu Cui
Sifu Cui
SLShupeng Li
Shupeng Li
Glioblastoma is a highly aggressive and devastating brain malignancy with dismal prognosis and extremely limited therapeutic options. Identification of prognostic biomarkers and therapeutic targets from multi‐omics data is critical for improving patient outcomes. In this study, we investigated the clinical significance of cellular heterogeneity and super‐enhancer‐driven regulatory networks, which are critically implicated in glioblastoma progression and treatment resistance. We first performed scRNA‐seq to dissect tumour microenvironment heterogeneity, identifying 16 distinct cell clusters, including astrocytes, macrophages, and CD8+ T cells. CellChat analysis revealed key intercellular signalling pathways, with astrocytes and macrophages acting as central communication hubs. To integrate bulk RNA sequencing data, we applied the Scissor algorithm to identify survival‐associated cell states. By combining single‐cell and bulk transcriptomic data, we uncovered 642 survival‐related genes, including QKI and RBM47, which robustly predicted patient survival and immunotherapy response. Furthermore, WGCNA analysis identified seven co‐expression modules and super enhancer‐regulated networks orchestrated by transcription factors (RFX2, RFX4) and hub genes (NEAT1, CFLAR). These networks stratified patients into high‐ and low‐risk groups with significant survival differences. Collectively, our findings elucidate the intricate interplay between cellular heterogeneity and super enhancer‐driven gene regulation in glioblastoma, providing a translational framework for targeting oncogenic hubs and modulating microenvironment interactions.

9 June 2026 in Translational Stroke Research
Verified
Journal Article
Open access
ZJZhi-Cheng Jiang
Zhi-Cheng Jiang
QHQi-Fei Hu
Qi-Fei Hu
JHJia-Ming Huang
Jia-Ming Huang
XWXian-Wei Wang
Xian-Wei Wang
TLTong Lin
Tong Lin
SLShupeng Li
Shupeng Li
The online version contains supplementary material available at 10.1007/s12975-026-01457-2.